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Abstract
Malignant migrating partial seizures of infancy (MMPSI) is a rare and usually an
unrecognized epileptic syndrome of infancy. The first publication was presented by
Coppola and colleagues in 1995, and Dulac in 2005 summarized 24 patients’ follow-
up in the Saint Vincent de Paul Hospital in Paris. Clinical cases have demonstrated a
new epileptic syndrome, different from previously described forms of epileptic
encephalopathies of infancy for the whole world of epileptology. Seizure onset before
the age of 6 months but commonly start within a few weeks of birth. In the age of 1
to 10 months seizures become very frequent, polymorphic and usually get clustered
nature; mental and motor retardation is clear observed. Clinical manifestation of
seizures may include head and eyes version, lateralized clonic eyelid twitchings,
fixed gaze, tonic tension or clonias of one limb or hemispasms, axial tonic spasms,
chewing or sucking movements, episodes of apnea, flushing, hypersalivation, and
secondary generalized seizures. MMPSI could be also considered as a special type of
infantile status epilepticus. Video-EEG monitoring plays the most important role in
the MMPSI diagnosis. Ictal EEG patterns involve different areas of the cerebral
cortex of both hemispheres; initial zone of ictal patterns shifts from one region to
another. MMPSI is a drug-resistant epilepsy with serious prognosis.
Keywords: malignant migrating partial seizures of infancy, Coppola-Dulac
syndrome, status epilepticus in infancy, epileptic encephalopathy
1. Introduction
Malignant migrating partial seizures of infancy (MMPSI) is a rare and usually an
unrecognized epileptic syndrome of infancy. The International League Against
Epilepsy defines this form of epilepsy as follows: seizure onset in the first 6 months
of life, occurrence of almost continuous migrating polymorphous focal seizures,
combined with multifocal ictal EEG discharges, and progressive deterioration of
psychomotor development [1–3]. Exact criteria of MMPSI are not defined and are
being developed. According to the draft of the Classification of the Epilepsies 2001,
this syndrome refers to presumably symptomatic neocortical focal epilepsy. In the
new Classification of the Epilepsies 2017 (ILAE 2017), MMPSI has not found a
separate place, but it is implied that it includes in a group of developmental and
epileptic encephalopathy.
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This severe form of epilepsy was recently described. The first publication about
migrating partial seizures of infancy was presented by Coppola and colleagues in
1995 [1], and then personal observations were done by Gerard et al. [4] and by
Okuda et al. [5]. Veneselli et al. summarized previous observations and added three
own cases [6]. Coppola et al. in their remarkable report (1995) based on
neuropediatric department at the René Descartes University (Paris) presented 14
clinical cases of infants of both sexes with previously undescribed epileptic syn-
drome characterized by virtually continuous multifocal seizures. According to the
classical authors description, the first seizures occurred average at the age of 3
months without any significant previous events. During the period from 1 to
10 months, seizures became very frequent. Seizures were focal and had different
clinical characteristics; EEG revealed multiple epileptiform discharges arising inde-
pendently and with migration during subsequent seizures from one cortical region
to another. Patients had regression of psychomotor development, tetraparesis and
severe muscular hypotonia of axial muscles. Three of 14 patients died: one at the age
of 7 months, and other at the age of 7 and 8 years. Seizures were completely ceased
only in two patients. In most cases the cause of the disease was not identified; and
there were no family cases [1].
In 2005, Dulac summarized 24 patients’ follow-up (the largest number of veri-
fied cases in the world) in the Saint Vincent de Paul Hospital in Paris. Marsh et al.
[25] reported another six cases of MMPSI observed in the Philadelphia Children’s
Hospital University of Pennsylvania who met the criteria described by Coppola.
Presented clinical cases have demonstrated a new epileptic syndrome, different
from previously described forms of epileptic encephalopathies of infancy for the
whole world epileptology [3].
Synonyms of this epileptic syndrome in the world scientific literature are malig-
nant migrating partial seizures of infancy, migrating partial seizures of infancy,
malignant epilepsy of infancy with migrating multifocal seizures, Coppola-Dulac
syndrome, and most genetic verified cases, which can be referred to early infantile
epileptic encephalopathy type 14 (EIEE14).
2. Etiology
In most MMPSI cases, etiology remains unknown; familial cases are rare. In
observation by Dulac, relatives in 3 of 24 patients had febrile convulsions, and 4
patients had family history of epilepsy [3]. Multiple tests for inherited metabolism
defects had negative results [7].
2.1 Monogenic mutations with Mendelian type of inheritance
The first genetic sequencing for identification mutations specific for MMPSI was
carried out by Coppola et al. [8]. Was performed automatic sequencing of genes of
potassium (KCNQ2, KCNQ3) and sodium (SCN1A, SCN2A) ion channels in three
children with MMPSI but no mutation have been found. Mutational screening of
chloride (CLCN2) ion channel gene revealed a homozygous mutation G2003C
(exon 17), leading to a Ser/Thr substitution at the codon 668, in two of the three
patients. But the same variation has been found in 38 out of 100 control alleles [8].
At present time a number of monogenic mutations were identified in patients
with malignant migrating partial seizures of infancy. In catalog of human genes and
genetic disorders – Online Mendelian Inheritance in Man (OMIM), we could find
the following positions for MMPSI phenotype (Table 1):
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2.1.1 Early infantile epileptic encephalopathy type 3 (EIEE6; 609304)
Poduri et al. [9] reported about two sibs (brother and sister), born of consan-
guineous Saudi Arabian parents, with EIEE3 presenting MMPSI phenotype. EEG
showed abnormal spikes in various brain regions. Neurological signs included
hypotonia and brisk tendon reflexes; psychomotor development was delayed and
subsequently arrested. Brain MRI was normal in the boy but showed delayed
myelination and diffuse thinning of the corpus callosum in his sister. Two sibs had
polymorphic seizures including bilateral and hemiclonic convulsions, flushing of
the face, “staring,” and eventually bilateral eyelid blinking. The seizures in both
children were refractory to treatment. The boy developed seizure onset at 1 week of
age and died at 14 months; the girl presented first seizures at 2 weeks of age and
died at 47 months of age. They also had two healthy brothers. The research team
Phenotype
OMIM
classification
Phenotype
OMIM
number
Gene/
locus
Gene
OMIM
number
Location Mutation
variants
Inheritance References
Early infantile
epileptic
encephalopathy
type 3 (EIEE3)
609304 SLC25A22 609302 11p15.5 gly110arg;
(.0003)
AR Poduri
et al. [9]
Early infantile
epileptic
encephalopathy
type 6 (EIEE6)
607208 SCN1A 182389 2q24.3 ala1669gly
(.0023)
arg862gly
(.0024)
AD Freilich
et al. [10]
Carranza
Rojo et al.
[11]
Early infantile
epileptic
encephalopathy
type 13 (EIEE13)
614558 SCN8A 600702 12q13.13 phe846ser AD Ohba et al.
[12]
Early infantile
epileptic
encephalopathy
type 14 (EIEE14)
614959 KCNT1 608167 9q34.3 arg428glm
(.0001)
ala934thr
(.0002)
arg474his
(.0003)
ile760met
(.0004)
phe932ile
(.0009)
gly288ser
(.0010)
AD Barcia
et al., [13]
Vanderver
et al. [14]
Ishii et al.
[15]
Early infantile
epileptic
encephalopathy
type 16 (EIEE16)
615338 TBC1D24 613577 16p13.3 phe229ser
(.0005) +
cys156ter
(.0006)
AR Milh et al.
[18]
Progressive
microcephaly
with seizures
and cerebral and
cerebellar
atrophy
(MSCCA)
615760 QARS 603727 3p21.31 tyr57his
(.0003) +
arg515trp
(.0004)
AR Zhang et al.
[19]
Table 1.
Monogenic mutations as etiological factors of malignant migrating partial seizures of infancy
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analyzed consanguineous pedigree (parents are cousins) and obtained DNA from
affected and unaffected family members, analyzed single nucleotide polymorphism
(SNP) 500 K data to identify regions with evidence for linkage, performed whole-
exome sequencing, analyzed homozygous variants in regions of linkage to identify a
candidate gene, and performed functional studies of the candidate gene SLC25A22.
In affected siblings, a homozygous c.328G-C transversion in the SLC25A22 gene was
identified, resulting in a gly110-to-arg (G110R; 609302.0003) substitution at a
highly conserved residue in the third transmembrane helix [9].
2.1.2 Early infantile epileptic encephalopathy type 6 (EIEE6; 607208)
It is a well-known fact that mutation in SCN1A is a leading etiological factor for
severe myoclonic epilepsy of infancy (Dravet syndrome). OMIM genetic classifica-
tion is early infantile epileptic encephalopathy type 6 (607208) with autosomal
dominant inheritance. Nevertheless, Freilich et al. [10] have found a novel mutation
in the SCN1A gene in the girl with MMPSI who died at the age of 9 months from
recurrent status epilepticus (SE). This girl had a severe phenotype, with onset of
seizures at age 10 weeks, progression to refractory recurrent seizures by age
5 months, SE of migrating multifocal seizures confirmed by EEG monitoring, pro-
gressive microcephaly, and profound psychomotor delay. By sequencing genomic
DNA from blood, the heterozygous missense mutation c.C5006C > A transversion
in the SCN1A gene, resulting in an ala1669-to-glu (A1669E; 182389.0023), which
further was confirmed in brain DNA, was identified. The resulting amino acid
substitution p.A1669E alters an evolutionarily conserved residue in an intracellular
linker of domain 4 of the SCN1A sodium channel protein [10].
In a scientific group of Epilepsy Research Centre, Department of Medicine,
University of Melbourne, Australia, Carranza Rojo et al. [11] have investigated 15
unrelated children with MMPSI for mutations in genes associated with infantile
epileptic encephalopathies (SCN1A, CDKL5, STXBP1, PCDH19, and POLG). One
girl with seizure onset at 2 weeks had heterozygous missense mutation de novo
2584C-G transversion in exon 14 of the SCN1A gene, resulting in an arg862-to-gly
(R862G; 182389.0024) that affects the sodium channel by substitution in the volt-
age sensor segment S4 of the second protein domain. She had epilepsy onset of
alternative hemiclonic seizures (Dravet-like onset) at the age of 2 weeks with
developing status epilepticus of multifocal migrating seizure. Also, the girl had
acquired microcephaly, developmental regression, and severe intellectual disability
with much more severe phenotype than children with Dravet syndrome. And,
another girl who developed MMPSI at the age of 2 months had de novo 11.06 Mb
deletion of chromosome 2q24.2q31.1 encompassing more than 40 genes that
included SCN1A. Screenings of CDKL5, STXBP1, and PCDH19 and the three com-
mon European mutations of POLG were negative [11].
Along with Dravet and MMPSI syndromes, mutation in SCN1A gene has been
also associated with generalized epilepsy with febrile seizures plus type 2 (604403),
familial febrile seizures type 3A (604403), and familial hemiplegic migraine type 3
(609634). All the diseases have autosomal dominant inheritance.
2.1.3 Early infantile epileptic encephalopathy type 13 (EIEE13; 614558)
Ohba et al. [12] identified in seven unrelated patients with early-onset epileptic
encephalopathies seven different de novo heterozygous missense mutations in
the SCN8A gene, and one of them had MMPSI. In a 5-year-old bedridden severe
delayed and profound intellectual disabled Japanese boy by whole-exome sequenc-
ing, de novo previously not described mutation in SCN8A gene c.2537 T > C
4
Epilepsy - Advances in Diagnosis and Therapy
(p.Phe846Ser) was detected. He developed apnea seizures from the age of 2 months
and further at 4 months demonstrated migrating hemiclonic convulsions increasing
up to status epilepticus of multifocal migrating seizures. MRI has shown mild atro-
phy of the cerebellum and thin corpus callosum. High-dose combined antiepileptic
therapy with phenobarbital, phenytoin, and lamotrigine, ketogenic diet, and vagus
nerve stimulator (VNS) implantation are temporarily and partially effective [12].
Voltage-dependent sodium channels, such as SCN8A, are responsible for the
initial membrane depolarization that occurs during generation of action potentials
in most electrically excitable cells. Mutations in KCNT1 aside from EIEE13 also
determine benign familial infantile seizures type 5 (OMIM 617080) and cognitive
impairment with or without cerebellar ataxia (OMIM 614306) with autosomal
dominant inheritance.
2.1.4 Early infantile epileptic encephalopathy type 14 (EIEE14; 614959)
Barcia et al. in 2012 had identified four different de novo heterozygous muta-
tions in the KCNT1 gene (608167.0001–608167.0004) in 6 of 12 unrelated pediatric
patients (50%) with clinically manifestation as MMPSI. The gene KCNT1 encodes a
sodium-activated potassium channel that is widely expressed at the nervous system.
Its activity contributes to the slow hyperpolarization as the neuronal membrane
potential that follows repetitive firing. The C-terminal cytoplasmic domain inter-
acts with a protein network, including FMRP (fragile X mental retardation protein),
suggesting additional functions [13].
OMIM genetic classification for this type of MMPSI is early infantile epileptic
encephalopathy type 14 (614959). At present time, the following allelic variants of
KCNT1 gene mutation in patients with MMPSI were identified:
ARG428GLN (608167.0001 KCNT1). It was founded by Barcia et al. [13] in
three unrelated patients of French origin and was identified as de novo heterozy-
gous 1283G-A transition in exon 13 of the KCNT1 gene, resulting in an arg428-to-
gln substitution at a highly conserved residue in the cytoplasmic C-terminal
domain.
ALA934THR (608167.0002 KCNT1). In a child of French origin with MMPSI,
Barcia et al. [13] identified a de novo heterozygous 2800G-A transition in exon 24
of the KCNT1 gene, resulting in an ala934-to-thr substitution at a highly conserved
residue in the cytoplasmic C-terminal domain. The mutation was shown to cause
constitutive activation of the sodium-activated potassium channel, mimicking the
effects of phosphorylation of the C-terminal domain by protein kinase C activation.
ARG474HIS (608167.0003 KCNT1). It was identified in a patient of French
origin with MMPSI by Barcia et al. [13] as de novo heterozygous 1421G-A transition
in exon 15 of the KCNT1 gene, resulting in an arg474-to-his substitution at a highly
conserved residue.
ILE760MET (608167.0004 KCNT1). It was also founded by Barcia et al. [13] in a
child of Ukrainian origin with early clinical manifestation of MMPSI and was
identified as de novo heterozygous 2280C-G transversion in exon 20 of the KCNT1
gene, resulting in an ile760-to-met substitution at a highly conserved residue.
All these mutations were identified by exome sequencing and also were con-
firmed by Sanger sequencing. Mutations were not found in 200 controls or in
several large control databases [13].
PHE932ILE (608167.0009 KCNT1). Vanderver et al. [14] identified in an
Australian boy the de novo heterozygous c.2794 T-A transversion in the KCNT1
gene, resulting in a phe932-to-ile substitution at a highly conserved residue in the
cytoplasmic C-terminal domain. This mutation was found by whole-exome
sequencing, confirmed by Sanger sequencing, and was not present in the 1000
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Genomes Project or Exome Sequencing Project databases. Seizure onset was at age
of 1 month with refractory myoclonic seizures that progressed to different poly-
morphic seizure types and status epilepticus. He also had microcephaly and severe
developmental stagnation. Brain imaging showed serious delayed myelination, and
EEG demonstrated background slowing with multifocal interictal discharges and
occasional periods of burst suppression. The patient doesn’t have classical MMPSI
characteristics and survived (last observation at the age of 10) with a decrease of
pharmacoresistant seizures at the age of 7 [14].
GLY288SER (608167.0010 KCNT1). Ishii et al. in two unrelated Japanese girls
with MMPSI identified a de novo heterozygous c.862G-A transition in the KCNT1
gene, resulting in a gly288-to-ser substitution at a highly conserved residue in the
pore region of the channel [15].
Kawasaki et al. described three infants with malignant migrating partial seizures
with KCNT1 mutations accompanied by massive systemic to pulmonary collateral
arteries with life-threatening hemoptysis and heart failure [16].
Madaan with colleagues from Child Neurology Division, Department of Pediat-
rics, All India Institutes of Medical Sciences (New Delhi, India), in 2018 identified a
child with MMPSI who had a novel heterozygous missense mutation in exon 10 of
the KCNT1 gene (chr9:138650308; c.808C > C/G (p.Q270E)). Neither quinidine
nor ketogenic diet could control his seizures, and the child succumbed to his illness
at 9 months of age [17].
My personal observation consists of two Russian girls with MMPSI having
KCNT1 mutations: one with gly288ser (608167.0010 KCNT1) and the other with
previously not described mutations c.1066C > T (arg356trp) in exome 12
(chr9:138656907C > T, rs752514808). So, it seems that KCNT1 is a major disease-
associated gene for the MMPSI phenotype.
It is interesting that mutations in KCNT1 also determine another form of
epilepsy – nocturnal frontal lobe epilepsy type 5. But the mutation is different from
the cases of MMPSI and is marked .0005–.0008 (ARG928CYS, TYR796HIS,
ARG398GLN, and MET896ILE).
2.1.5 Early infantile epileptic encephalopathy type 16 (EIEE14; 615338)
Milh et al. [18] identified compound heterozygosity for two mutations in exon 2
of the TBC1D24 gene (686 T-C transition, resulting in a phe229-to-ser,
613577.0005, and 468C-A transversion, resulting in a cys156-to-ter, 613577.0006)
in two sisters with malignant migrating partial seizures of infancy. These girls early
developed clonic seizures in the second month of life and subsequently demon-
strated prolonged, almost continuous migrating seizures of different types with
severe neurologic deterioration and lack of psychomotor development [18].
OMIM genetic classification for this type of MMPSI – early infantile epileptic
encephalopathy type 16 (615338). The screening of TBC1D24 in an additional set of
eight MMPSI patients observed by Milh and colleagues was negative. The TBC1D24
gene encodes a member of the Tre2-Bub2-Cdc16 (TBC) domain-containing RAB-
specific GTPase-activating proteins, which coordinates peripheral membrane Rab
proteins and other GTPases for the proper transport of intracellular vesicles.
Coimmunoprecipitation studies showed that the phe229ser mutation impaired the
interaction of TBC1D24 with adenosine diphosphate (ADP)-ribosylation factor 6
(ARF6, 600,464), and overexpression of the mutant protein in primary cortical
neurons abolished the ability of TBC1D24 to increase neurite length and arboriza-
tion, consistent with a loss of function [18].
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Mutation in TBC1D24 gene has been also associated to infantile familial myo-
clonic epilepsy (OMIM 605021, autosomal recessive inheritance), DOORS
syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation, and
seizures syndrome – OMIM 220500) with autosomal recessive inheritance, and also
autosomal recessive deafness type 86 (614617), and autosomal dominant deafness
type 65 (616044).
2.1.6 Progressive microcephaly with seizures and cerebral and cerebellar atrophy
(MSCCA; 615760)
Zhang et al. [19] in four patients from two unrelated families with progressive
microcephaly, intractable seizures, and cerebral and cerebellar atrophy (MSCCA;
615,760) identified compound heterozygous mutations in the QARS gene
(603727.0001–603727.0004). The mutations were found by whole-exome sequenc-
ing and confirmed by Sanger sequencing. QARS (or GLnRS; 603,727) is a class I
aminoacyl-tRNA synthetase. Aminoacyl-tRNA synthetases are enzymes that charge
tRNAs with their cognate amino acids. The specificity of this reaction determines
the fidelity of mRNA translation. At least one synthetase exists in the cytoplasm for
each amino acid. QARS is essential for normal brain development. Studies in patient
cells and expression of recombinant variants in E. coli showed that all four muta-
tions caused a severe loss of QARS catalytic activity, consistent with a loss-of-
function effect. Homozygous loss of QARS in zebrafish caused decreased brain and
eye size and extensive cell death in the brain. Two sibs observed by Zhang et al.
[19], born of unrelated French parents, had clinical and EEG signs of malignant
migrating partial seizures of infancy and compound heterozygous mutations in the
QARS gene, a c.169 T-C transition, resulting in a tyr57-to-his (603727.0003) sub-
stitution at a highly conserved residue in the N-terminal domain, and a c.1543C-T
transition, resulting in an arg515-to-trp (603727.0004) substitution at a highly
conserved residue in the catalytic domain. Patient cells showed decreased
aminoacylation activity of QARS compared to control. Expression of recombinant
arg515trp (.0004) in E. coli resulted in no QARS catalytic activity, whereas tyr57his
(.0003) decreased QARS activity to less than 10% that of controls. In addition, the
arg515trp mutation appeared to cause protein misfolding and aggregation, resulting
in decreased expression of the soluble mutant protein [19].
2.1.7 Rhizomelic chondrodysplasia punctata type 2 (RCDP2; 222765)
On personal observation of MMPSI patients, one Russian boy with clinical and
electroencephalographic pattern of mixed form (MMPSI and early myoclonic
encephalopathy) had rhizomelic chondrodysplasia punctata type 2 (RCDP2;
222,765) from the group of peroxisomal metabolic diseases [20]. Rhizomelic
chondrodysplasia punctata type 2 (RCDP2) is caused by homozygous or compound
heterozygous mutation in the DHAPAT gene (GNPAT; 602,744), which encodes
acyl-CoA:dihydroxyacetonephosphate acyltransferase, on chromosome 1q42. This
peroxisomal disorder is characterized by disproportionately short stature primarily
affecting the proximal parts of the extremities, a typical facial appearance including
a broad nasal bridge, epicanthus, high-arched palate, micrognathia, dysplastic
external ears, eye abnormalities‑cataract and coloboma, congenital contractures,
dwarfism, hypotonia, and severe mental retardation. Biochemically, plasmalogen
synthesis and phytanic acid alpha-oxidation are defective.
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2.2 Chromosome aberrations
At 2010 group of genetics from the Department of Pediatrics, University of
Michigan (Ann Arbor, Michigan, USA), has found de novo 598 kb 16p11.2
microduplication in a boy with refractory MMPSI, who has developed seizures in
4 months and also has spastic quadriparesis, severe global developmental delay,
hypotonia, and microcephaly [21].
In 2012 Poduri and colleagues from the Department of Neurology of Children’s
Hospital Boston (Massachusetts, USA) in a patient, born of consanguineous Pales-
tinian parents, with clinical manifestation as MMPSI, identified a homozygous 486-
kb deletion on chromosome 20p12.3 encompassing the promoter region and exons
1, 2, and 3 of the PLCB1 gene. The deletion breakpoints were mapped from
8,094,049–8,094,072 to 8,580,261–8,580,284 (GRCh37). The breakpoints lie within
two LINE nuclear elements and likely arose from nonallelic homologous recombi-
nation. PLCB1 gene (607,120; locus 20p12.3) is responsible for early infantile epi-
leptic encephalopathy type 12 (EIEE12; 613,722). Phospholipase C-beta (PLCB)
catalyzes the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) from phosphatidylinositol 4,5-bisphosphate (IP2), a key step in the intra-
cellular transduction of many extracellular signals. The PLCB1 gene encodes a
mammalian PLCB isoform that is expressed in cerebral cortex, hippocampus,
amygdala, lateral septum, and olfactory bulb [22].
2.3 Other etiological factors
Most cases of MMPSI are considered as unknown etiology (cryptogenic). But
also MMPSI had its symptomatic analogs including cases considered as dual pathol-
ogy [1–3, 20, 23].
In two of three cases for the first time presented by Coppola et al., neuropatho-
logic brain examination showed marked loss of hippocampal neurons in combina-
tion with gliosis in the CA1 sector of hippocampal pyramidal layer [1, 23].
Personal observation of 35 cases with MMPSI contains 12 children with symp-
tomatic clinical-electroencephalographic copies of MMPSI (5 boys and 7 girls). Only
two infants had cerebral dysgenesis: lissencephaly-pachygyria in one girl and
polymicrogyria in another girl. Other ten children had severe perinatal hypoxic-
ischemic CNS disturbances (four of them mixed with perinatal infections‑cytome-
galovirus, ureaplasma, chlamydia, herpes type 1) that caused serious brain damage,
tetraparetic spastic form of cerebral palsy, and severe retardation in combination
with epileptic encephalopathy. Their clinical and video-EEG signs demonstrated
MMPSI picture.
3. Clinical signs
At the present time, at least about 100 cases of MMPSI appear to be described in
the world literature. However, the number of publications has been steadily grow-
ing in recent years. Obviously, this serious disease is more common than diagno-
sed due to the low clinicians’ awareness. In the structure of patients with onset of
status epilepticus before 3 years of age (n = 267), a group of children with MMPSI
consisted 4.9% (n = 13), and in the structure of infant with SE (n = 147) – 8.8% [24].
Both sexes are equally susceptible. According to Dulac, 20 children with MMPSI
included 9 girls and 11 boys [3]. Disease onset varies in age from 1 week to 7 months
of life (average – 3 months) [1, 4]. According to Marsh et al., seizures onset varied
from the first days to 3 months (average – 25 days) [25].
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In most cases, pattern of the first seizure includes motor component of one limb
or half of the body; and 50% of the patients develop secondary generalization. In
some cases after seizure onset, their frequency uncontrolled rapidly rises to status
epilepticus. However, seizures could have longer duration, but at onset seizures
often go unrecognized. Cases with autonomic manifestation (episodes of apnea,
short blackouts with cyanosis or redness) are difficult to diagnose [3]. Thus, in
observation by Gerard et al. [4], epileptic seizures with diffuse erythema and
sweating with subsequent hiccups were reported as gastroesophageal reflux, and
only a few weeks later, addition of focal seizures was noted, which made diagnosis
obvious [4]. According to observations by Dulac, the initial period of the disease
usually lasts from 1 week to 3 months (average – 45 days). During this period,
seizures may be quite rare, for example, once a week [3].
In the age of 24 days to 10 months (mean 4.5 months), seizures become very
frequent and polymorphic but usually are still focal. Seizures usually get clustered
(serial) nature, mental and motor retardation is clear. Clinical manifestation of
seizures may include head and eye version, lateralized eyeball twitching, fixed gaze,
clonic eyelid twitching, tonic tension or clonic spasms of one limb or hemispasms,
axial tonic spasms, chewing or sucking movements, episodes of apnea, flushing,
hypersalivation, and secondary generalized seizures. One patient may have multiple
different combinations of seizures. Typically, seizure duration is 1–4 minutes, but
in some cases, it may persist up to several 1 of minutes, until the status epilepticus
development. As far as the disease progresses, secondary generalized seizures
became more frequent. Seizures are almost continuous or occur as a series 5–30
times per day, mainly on awakening and when falling asleep. Seizure periods may
alternate with clear periods when seizures occur within 2–5 days continuously, and
then there are several “light” days (the cyclic course of disease) [1–3, 26].
It should be considered that many seizures are hardly noticeable visually
and often remain unrecognized for parents and medical staff. In particular, these
are “volatile” paroxysms, as short episodes of apnea, episodes of eyes closing or eyes
deviation, episodes of facial flushing, etc. Only video-EEG monitoring can prove
the epileptic genesis of paroxysmal phenomena.
The course of the disease and the severity of clinical symptoms often have
undulating pattern: a period of severe illness and permanent seizures may continue
for several weeks, and then it is replaced by a relatively favorable period of the
temporary seizure regression and some improvement in cognitive and motor func-
tions. This phenomenon generates additional difficulties in controlling the quality
of care as it is quite difficult to differentiate in which case the decrease in frequency
and severity of seizures is a true response to therapy and in which case it is subject
to the course of the disease.
Under personal observation of patients with MMPSI, age of seizure onset ranged
from the 1st day of postnatal life up to 6 months of life. MMPSI were characterized
by marked polymorphism (Table 2) and high frequency of epileptic seizures and
were in fact a special form of infantile status epilepticus (SE) in the form of
migrating multifocal SE. All patients had five or more types of epileptic seizures.
Neurological findings in MMPSI children marked with neurological impairment
from birth‑severe central tetraparesis, often with muscular hypotonia in the axial
and limb muscles [1], microcephaly, strabismus, and athetoid hyperkinesis [25]‑are
common. Many patients in dynamics are unable to walk and sit without support
and in severe cases are also unable to control the vertical head position, drink,
and swallow. In all cases, there is mental retardation, usually severe, and visual
agnosia [3].
Personal patients with MMPSI (n = 35) in neurological status had a high repre-
sentation of various disorders: high level of stigmatization was observed in 15
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patients (42.8%), 13 patients (37.1%) had microcephaly, and optic nerve atrophy
was observed in 27 patients (77.1%). Disorders of bulbar innervation were observed
in all patients, while in nine children (25.7%), these impairments were bulbar
syndrome, and in 26 children (74.3%) – pseudobulbar syndrome. All patients with
MMPSI had changes in the muscle tone: 10 children (28.6%) had spastic
hypertonus, 16 children (45.7%) had diffuse muscle hypotonia, and 9 children had
dystonic changes (25.7%). Severe movement disability with tetraparesis was formed
in all of the children with MMPSI. Neurological disorders were expressed at birth
(n = 16, 45.7%) or developed with the onset of seizures (n = 19, 54.3%) and tended
to a steady progression in all the patients. All children with MMPSI had delay of
motor and mental development (n = 35, 100%), up to a complete development stop
in 26 infants (74.3%).
4. Electroencephalographic findings and neuroimaging
4.1 EEG and video-EEG monitoring
Diffuse slowing of the main background activity is typical that is revealed in the
first EEG recordings. At first epileptic cause of these EEG phenomena may remain
Seizure types Patients (n) %
Tonic versive seizures 35 100
Tonic spasms 33 94.3
Ophthalmo-tonic seizures 35 100
Ophthalmo-clonic seizures 11 31.4
Atonic seizures 23 65.7
Dialeptic (pseudoabsences) 19 54.3
Pharyngo-oral seizures 18 51.4
Tongue clonus 7 20
Hemiclonic 19 54.3
Jacksonian march 11 31.4
Automotor 8 22.9
Apnea with cyanosis 14 40
Autonomic with vomiting 5 14.3
Focal myoclonic 18 51.4
Bilateral myoclonic 13 37.1
Fragmentary “erratic” myoclonus 5 14.3
GTCS 14 40
SE of migratory minor motor seizures 35 100
SE of inhibitory seizures 12 34.3
Hemiconvulsive SE 11 31.4
SE of tonic spasms 10 28.6
Myoclonic SE 9 25.7
SE of GTCS 8 22.9
Table 2.
Epileptic seizure types in patients with malignant migrating partial seizures of infancy (n=35)
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undetected, especially if symptoms include only short autonomic paroxysms. Epi-
leptiform disorders in disease onset are rare. However, in 3 of 14 patients in the
observation by Gerard et al. [4], originally normal background EEG was observed;
later, slowing with variable asymmetry was recorded in all cases. Often, slow-wave
accentuation in one of the EEG recordings is more pronounced in one hemisphere,
while the later study may reveal dominating slow-wave lateralization from the
opposite side. Multiregional spikes without clear activation during sleep are regis-
tered in all cases during development of the disease. However, pathognomonic
interictal EEG pattern in MMPSI is absent. During the period relatively free of
seizures, stage differentiation in the structure of sleep EEG may persist, but sleep
spindles are rare and usually asymmetric [3]. When seizures become very frequent,
interictal activity is almost absent.
Ictal EEG patterns involve different areas of the cerebral cortex in the course of
successive seizures. Ictal pattern is a rhythmic activity of alpha and theta range,
occurring in one region with adjacent regions involvement during seizure, followed
by a gradual decrease of the frequency characteristics. Caraballo with colleagues,
analyzing 17 infants with MMPSI, had distinguished three different EEG patterns: 8
cases with alternating simple focal motor seizures at onset, and the ictal EEG
pattern was characterized by recurrence of rhythmic focal spikes or rhythmic sharp
theta or alpha activity in the Rolandic region; 5 cases with complex focal seizures
and progressive appearance of polymorphic theta-delta in temporo-occipital regions
recurring independently; and 4 cases with focal complex seizures with motor man-
ifestations and ictal EEG with flattening or fast activity in frontotemporal region
followed by unilateral fast polyspikes in alternating clusters in both hemispheres.
Correlations between these three patterns with severity or prognosis were not
found [27]. Electro-clinical seizure patterns last from 1 to 4 minutes. Multiple
subclinical ictal EEG patterns lasting from 30 seconds to 1 minute are also typical
[1]. Observations show an alternative cortical section of both hemispheres’
involvement in epileptogenesis, which implies the presence of a diffuse pathological
process in the cerebral cortex [3].
When seizures become very frequent, initial zone of ictal pattern shift from one
region to another and from one hemisphere to another occurs. As a result, extended,
migratory ictal activity, which forms a complex EEG pattern of status epilepticus,
develops [1–3].
Video-EEG monitoring plays the most important role in the MMPSI diagnosis, as
it is able to detect a correlation between ictal pattern localization of and clinical
characteristics of seizure. Thus, ictal pattern in the frontal region produces clinical
signs in the form of tonic tension or clonic spasms in the contralateral limb; ipsilat-
eral automatisms or a versive seizure with alternating tonic phenomena and fencing
posture are possible. EEG pattern is localized in perirolandic area and manifests
with contralateral clonus of the lips, tongue, facial muscles, and hypersalivation.
Temporal EEG patterns clinically manifest with broad “frozen” gaze (“staring”
phenomenon) and oro-alimentary automatisms. Ictal EEG patterns originating
from occipital cortex correlate with lateralized clonic eyes and head twitching. In
the case of parietal pattern, nonspecific motor activity is possible; sometimes, a
child seems “listening” to his/her inner feelings. The above phenomena are contrary
to a prevailing opinion that there is no clear clinical-electroencephalographic corre-
lation of focal ictal patterns in infants and rather suggest the opposite.
As child grows, the amplitude of ictal activity tends to increase with growing
involvement of the frontal lobes; many seizures become secondarily generalized.
The phenomenon of secondary bilateral synchronization typically occurs after only
a few weeks from the onset [1]. However, Gerard et al. [4] in the last observations
found a delay of bilateral synchronization and additional foci of epileptiform
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activity generation, at least up to 2 months from the onset (possibly as antiepileptic
drug effect) [4]. At this stage detection of early drug resistance may result to a
wrong decision about surgical treatment. Extended video-EEG monitoring also has
a considerable importance in this category of patients, because visualization of
seizures originating from the same cortex area does not mean that all seizures
originate only from this area [28].
Despite the various topographies, ictal EEG patterns of all episodes are very
similar and correspond to rhythmic activity of the alpha or theta range, prone to the
spread and involving all large cortex areas [7].
EEG in personal patients (n = 35) was characterized by diffuse slowing of back-
ground activity, while in the developed stage, background EEG was almost
completely replaced by continuous ictal patterns. In the initial stages of the disease,
interictal record revealed regional or multiregional epileptiform discharges with for-
mation of multifocal independent spike foci (MISF) pattern. Most cases of MMPSI
(20 patients, 57.1%) initially had MISF with transformation in MMPSI as frequency
of epileptic seizures increased and migratory status developed. In seven cases (20%),
monofocal epilepsy was initially observed, followed by addition of extra foci, new
types of seizures, and increase of multifocal ictal events up to SE. At eight infants
(22.9%), the first properly done EEG investigation fixed the multiregional SE pattern
with its preservation in dynamic video-EEG studies and negative prognosis for live.
Ictal EEG patterns in the developed stage of MMPSI involved different areas of
the cerebral cortex during a series of seizures, which could overlap each other in
cases when ictal pattern in one area is not yet over, but the same pattern appeared in
other cortical areas. There may be a complex picture, combining postictal changes
in one region of the cerebral cortex, initial ictal pattern in another area, and devel-
oped ictal pattern in the third. Typical EEG pattern of MMPSI is presented in a
series of electroencephalograms (Figures 1–7). In general, ictal pattern
Figure 1.
Patient G.E., 1 year old. Diagnosis: Malignant migrating partial seizures of infancy. EEG during status seizures.
Emergence of regional ictal EEG pattern in the left frontal region in the form of fast epileptiform activity and
transformation to regular activity of theta range with amplitude increase and sharp wave inclusion. In the left
parietal, posterior temporal region is seen delta-accentuation after the previous seizure. Manifestation: Right-
sided tonic seizure with oro-facial and versive components.
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demonstrates migration of paroxysmal ictal characteristics from one region to
another, without formation of stable interregional relations. Probably, only due to
ictal pattern migration, patients are able to stay in SE of focal seizures for a long
time without development of life-threatening cerebral edema.
Figure 2.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity involves neighboring regions and same
areas of the right hemisphere, but with maintenance of left-sided lateralization. Manifestation: Bilateral tonic
seizure.
Figure 3.
The same patient. Continuation of ictal EEG. Ictal epileptiform activity in the frontal areas changes to the right-
sided lateralization. Manifestation: Transformation to asymmetric tonic seizure with left-sided accentuation.
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The following variants of ictal patterns have been identified in patients with
MMPSI: regional “saw tooth” activity of alpha and theta range; “lafa” runs were
obligate ictal patterns and were detected at all patients with MMPSI; frequently
Figure 4.
The same patient. Continuation of ictal EEG. Diffuse spread of ictal epileptiform activity with multiple spikes.
On this background, emergence of regional accentuation of ictal pattern in the left parietal-posterior temporal
region. Manifestation: Transformation to generalized tonic seizure with clonic component.
Figure 5.
The same patient. Continuation of ictal EEG. Slowing down of frequency characteristics of the diffuse ictal
pattern with transformation to the delta slowing. In the opposite left parietal-posterior temporal region,
activation of the regional ictal pattern with regionally accentuated polyspikes and spike-wave complexes is seen.
Manifestation: Transformation to asymmetric tonic seizure with right-sided clonic component.
14
Epilepsy - Advances in Diagnosis and Therapy
runs of fast regular spike-wave complexes were also identified; and runs of slow
regular spike-wave complexes (rarely), and diffuse spike- and polyspike-wave
discharges.
Figure 6.
The same patient. Continuation of ictal EEG. Shift of ictal pattern in the left parietal-posterior temporal region
to the delta slowing with slow epileptiform complexes. At the same time in the right hemisphere, emergence of a
new ictal pattern in the form of low-amplitude fast activity (lafa). Manifestation: Short-term decrease of
clinical ictal severity.
Figure 7.
The same patient. Continuation of ictal EEG. Ictal pattern in the right hemisphere in the form of regular alpha-
theta activity with frontal-central accentuation. Postictal changes in the left hemisphere in the form of
depression of the bioelectric activity with delta rhythm dominance. Manifestation: Asymmetrical tonic seizure
with left-sided accentuation.
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Along with “classical” EEG pattern of MMPSI, atypical mixed variants were
observed in the manner of superposition of continuous migratory multiregional SE
pattern to suppression-burst pattern with diffuse polyspike-wave discharges
(Figures 8–10). Five of these infants (three boys and two girls) had a special mixed
form of epilepsy in the form of MMPSI combination with early myoclonic enceph-
alopathy (EME) with the presence of multiple fragmented “erratic” myoclonus
along with migrating focal status seizures.
Such mixed form with transformation of EME into MMPSI was also described by
specialists from the Department of Pediatrics of the Taipei City Hospital Zhongxing
Branch (Taipei, Taiwan) in a female neonate [29].
4.2 Neuroimaging
According to the world literature, CT and MRI changes are absent, and the
majority of MMPSI cases are regarded as cryptogenic. Atrophic changes are
nonspecific and further are exacerbated by the constant epileptic seizures [1, 25].
Figure 8.
Patient P.S., age 1 year and 1 month old. Ictal EEG. Diagnosis: Mixed form of MMPSI + EME.EEG reveals
combination of suppression-burst pattern with polyspike waves and focal ictal patterns in the left frontal and
right temporal areas independently.
Figure 9.
The same patient. Continuation of ictal EEG. EEG reveals combination of suppression-burst pattern and focal
ictal patterns in the left centro-parietal area with central sagittal (vertex accent).
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Coppola et al. found left temporal lobe dual pathology in a child with MMRSI,
including hippocampal sclerosis and cortical-subcortical blurring [23]. Caraballo
et al. reported about mesial temporal lobe sclerosis in 3 of 17 patients [27]. Gross-
Tsur et al. presented patients with MMPSI decreased N-acetyl aspartate in the
frontal cortex and basal ganglia revealed by MR brain spectroscopy [30].
In cases of cryptogenic MMPSI, minimal or moderate subatrophic changes ini-
tially were fixed, sometimes in combination with a moderate delay of myelination,
but with progressive cerebral atrophy at 11 children with persistent
pharmacoresistant seizures. Dysgenetic brain malformations were found at neuro-
imaging only in two children with symptomatic analogs of MMPSI in the form of
lissencephaly-pachygyria in one girl and polymicrogyria in another girl. Remaining
ten patients with symptomatic analogs of MMPSI had a wide range of hypoxic-
ischemic CNS lesions in the form of periventricular leukomalacia, parasagittal
Chugani necrosis, and diffuse cortical-subcortical atrophy (“walnut” brain).
5. Treatment
MMPSI is a drug-resistant epilepsy form with serious prognosis. Treatment
approaches are still developing. Baseline, old, and new antiepileptic drugs in
various combinations, as well as corticosteroids, are ineffective [1–3].
However, Dulac observed seizure aggravation during treatment with carbamaz-
epine and vigabatrin in these patients [3]. Perez et al. observed temporary
seizure remission in two cases of MMPSI with combination of stiripentol (met-
abolic drug, inhibitor of several cytochrome P-450 enzymes) and high doses
of clonazepam [31]. Hmaimess et al. published about effectiveness of
levetiracetam in MMPSI [32]. Okuda et al. [5] reported efficacy of potassium
bromide in migrating partial seizures of infancy. A 3-month-old boy and a
4-month-old girl with failure of common antiepileptic drugs reached complete
remission of seizures in one case and significant decrease of seizure frequency
(95%) in another case due to treatment with potassium bromide 80 mg/kg/day
[5]. In all cases of seizure control, gradual improvement in psychomotor devel-
opment of children was observed that also proves the leading role of epilepti-
form activity and persistent seizures in the development of epileptic
encephalopathy [3].
Figure 10.
The same patient. Continuation of ictal EEG. EEG reveals combination of suppression-burst pattern and focal
ictal pattern in right occipital-posterior temporal area.
17
Malignant Migrating Partial Seizures of Infancy (Coppola-Dulac Syndrome)
DOI: http://dx.doi.org/10.5772/intechopen.82838
Chien et al. have stopped erratic myoclonus and suppressive-burst pattern on
EEG in a mixed form of EME + MMPSI using dextromethorphan 20 mg/kg [29].
There are different opinions about usefulness of ketogenic diet in MMPSI. So,
François et al. proclaimed that seizures in MMPSI are also resistant to ketogenic diet
[33]. But specialists from Children’s Neuroscience Centre of Royal Children’s Hos-
pital (Parkville, Victoria, Australia) published data about efficacy of the ketogenic
diet in children with this pharmacoresistant form of epilepsy [34].
Surgical treatment of MMPSI is unreasonable because of diffuse nature of brain
damage and lack of clear local structural defect [3]. Theoretically, anterior
callosotomy may be offered as a palliative intervention; however, there is no such
experience in this form of epilepsy.
A group of scientists from the Pediatric Neurology Department of Azienda
Ospedaliera Universitaria (Ancona, Italy) have published about positive experience
of vagus nerve stimulation (VNS therapy) in three infants with pharmacoresistant
MMPSI [35].
Our cases confirmed that MMPSI are resistant to antiepileptic therapy.
Monotherapy had no significant effect in all patients. All patients with MMPSI
failed to relieve from epileptic seizures. In 14 MMPSI cases, antiepileptic therapy
was completely ineffective (56%), reduction of seizures >50% was observed in
seven patients (28%), and only in six patients decrease of seizures was >75%
(17.16%). Relatively effective combinations of antiepileptic drugs included
valproates with barbiturates (phenobarbital and hexamidine) and benzodiazepines.
Clobazam 1 mg/kg was most effective among benzodiazepine groups. In two
patients positive effect was observed with combination of levetiracetam, and in one
case – with combination of benzodiazepine and topiramate. Phenytoin in two cases
caused moderate positive effect with “escape effect.” In one patient, frequency of
seizures decreased during treatment with potassium bromide (50 mg/kg) but with
side effects in the form of hypersomnia. High doses of vitamin B6 in two cases were
moderately positive.
Ethosuximide, rufinamide, carbamazepine, and oxcarbazepine have no substan-
tial positive effect. In one case, carbamazepine in cryptogenic focal frontal epilepsy
with temporary positive effect caused subsequent aggravation of seizures with
appearance of additional foci with clinical and electroencephalographic transfor-
mation into MMPSI.
Hormone therapy caused only a temporary moderate positive effect in eight
cases and was completely ineffective at other cases.
For emergent relief of SE of hemiconvulsive and secondary generalized
tonic-clonic seizures in 15 cases of MMPSI, benzodiazepines (relanium and
midazolam) had only a temporary effect in eight or were completely ineffective
in seven cases.
Positive effect in SE in MMPSI was observed with sodium oxybate administra-
tion at a dose of 100–150 mg/kg, 400 mg/min. This was done in seven cases of
hemiconvulsive (n = 3) and secondary generalized tonic-clonic SE (n = 4) resistant
to benzodiazepines with a temporary regression (six cases) or a decrease of clinical-
EEG paroxysmal events (one case).
In three patients with MMPSI, intravenous valproates caused significant positive
effect in relieving SE, especially in cases of tonic-autonomic seizures with episodes
of apnea, with aggravation during treatment with benzodiazepines [36]. The
recommended dose was 25 mg/kg intravenous over 5 min with the following main-
tenance infusion – 2 mg/kg/h.
Sodium thiopental (4 mg/kg for 2 min and then infusion of 0.2 mg/kg per
minute) is the last chance to stop drug-resistant SE but caused death in one girl due
to central inhibition of cardiac activity.
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6. Prognosis
MMPSI is a form of epilepsy with poor prognosis. Within a few months after
disease onset, frequency and duration of seizures increase up to the serial seizures
and status epilepticus. A number of patients die in the first year of life due to
multiple prolonged epileptic seizures, development of respiratory distress syn-
drome, and decorticate rigidity [30]. Based on the generalized clinical observations,
mortality in this syndrome is 28% [3]. The results obtained by Marsh et al. are
prognostically more favorable: during the 7-year follow-up, all six patients sur-
vived; however, psychomotor retardation with severe muscular hypotonia persisted
in three of them, and only one patient reached seizure control for a long time [25].
Mortality at personal observed cases was 25.7% (n = 9); however, the expected
mortality is higher due to short follow-up (1 year) in more than half of these
patients. The oldest of the survived patients with MMPSI is 9 years old; there is
gross delay of psychomotor development with unformed verticalization skills,
absence of voice activity, spastic tetraparesis, and multiple focal asymmetric tonic,
versive, pharyngo-oral, and dialeptic seizures.
Follow-up of patients with MMPSI allowed distinguishing the following sub-
populations:
• “Classical” form in the form of marked SE of migrating multifocal seizures is
pharmacoresistant with a poor prognosis for psychomotor development,
seizures, and life (19 cases, 54.3%).
• Mixed form (MMPSI + EME) with a combination of electro-clinical MMPSI
characteristics but also with the presence of fragmented “erratic” myoclonus
and suppression-burst pattern with polyspike-wave discharges on EEG (five
cases, 14.3%) with also poor prognosis for mental and motor functions,
seizures, and life.
• “Moderate” or “mild” form with a consistent evolution from unifocal form to
multifocal form with EEG pattern MISF, and then developed expressed MMPSI
electro-clinical characteristics, but with a possible regression and decrease in
frequency of seizures during combined antiepileptic therapy (six cases, 17.1%).
• “Subtle” form, in the form of only “subtle” minimal motor seizures, inhibitory
seizures, multiple ictal patterns during sleep, and leading to awakening (five
cases, 14.3%). This form causes a rough developmental delay in infants, but
without video-EEG monitoring, it remains unrecognized [20].
7. Conclusions
MMPSI is an independent epileptic syndrome with special clinical-
neurophysiological characteristics, distinct from other forms of epilepsy. Diagnosis
can be established if there are different types of focal seizures, involving multiple
extended EEG and electro-clinical ictal EEG patterns with involvement of several
independent areas in both hemispheres. All the patients need complex investiga-
tions including dynamic video-EEG monitoring, neuroimaging, and genetic tests
(whole-exome sequencing is more preferable).
MMPSI should also be differentiated from the syndrome described by
Ohtahara – “severe epilepsy with multiple independent spike foci” (SE-MISF). In
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the literature, this form is also known as Markand-Blume-Ohtahara syndrome
[37]. Unlike MMPSI, this form manifests with predominantly pseudogeneralized
seizures: bilateral axial tonic spasms, atypical absences, and myoclonic but focal
seizures could also observed. But SE-MISF and MMPSI could have evolutional
changes into each other.
Therefore, malignant migrating partial seizures of infancy is the third type of
infantile epileptic encephalopathy, along with early encephalopathies with
suppression-burst pattern (Aicardi and Ohtahara syndromes) and West syndrome,
when the cerebral cortex is more prone to generate epileptic excitation migrating
from one area of the cortex to another, without clear interregional organization.
This condition is caused by age-dependent features of infant brain with cortex
hyperexcitability at a certain stage of evolution [3, 38].
The definition of this syndrome has not been defined in the international classi-
fication of epilepsies and epileptic syndromes. The term “malignant migrating
partial seizures of infancy” characterizes this form of epilepsy rather as syndrome,
so it is proposed to discuss the following title “malignant epilepsy of infancy with
migrating multifocal seizures” that may more fully capture the essence of the
disease. Taking into account contributions of scientists that first described this form
of epilepsy (Coppola) and gave the most detailed description of the clinical and
neurophysiological criteria (Dulac), the following definition is proposed: Coppola-
Dulac syndrome [39].
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